Cytorex Biosciences Inc (Cytorex), a South Florida biotechnology company with research and development facilities in Texas, announced today a corporate rebranding.
"Due to the fact that Cytorex Biosciences Inc. has achieved the goals established in the Research and Development plan outlined to comply with the pharmaceutical regulations required by the entities and the need to transmit the essence of our ion-based therapeutic technology, we considered it necessary to update our corporate image in order to face the new challenges to be met", explained William Jimenez, president of the company's board of directors.
"With this logo, based on the freshness of a silhouette of a drop with circles with negative and positive signs, we wanted to represent the essence of a drop of Cytoreg® ion therapy. For now, the therapy is presented in liquid form, and contains a variety of ions provided by the acids that make up its composition, whose conjugated bases have different electrical charges. These electric charges are of each ion, represented by the circles with the signs. Therefore, the therapeutic technology Cytoreg®, constitutes a complex of transport of ions, positively charged cations and negatively charged anions, in high concentrations that allow to regulate the mitochondrial and cellular metabolism", said William Jimenez, who invited to visit the web page www.cytorex.com.
About Cytorex Biosciences, Inc.
Cytorex Biosciences, Inc. is a small innovative biotechnology company based in South Florida with a research and development coordination center in Kingwood, Texas focused on the development and research of ionic therapeutic agents, based on Cytoreg® ionic therapeutic technology, for the development of targeted therapeutic agents for the treatment of pathologies such as cancer, autoimmune diseases, neurodegenerative diseases, kidney stones, bacterial-derived pathologies, viruses such as Ebola and SARS-CoV-2 among other pathologies. Cytorex has worldwide intellectual property rights on its technologies, with other new patents pending and others in development. Cytorex Biosciences Inc. is currently in the final stage of the preclinical phase for PRE-IND review by USFDA of its ionic therapeutic agent designed for the treatment of Glioblastoma Multiforme brain tumors.